Skip to content
Review

Rivastigmine-centered molecular hybridization strategies for multi-targeted intervention in Alzheimer's disease: Advances (2020-2026).

Sep 2026 · Bioorganic & Medicinal Chemistry · Vol 143, pp. 118811 · 0 citations · 96 references
Medicine

TL;DR

This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment.

Abstract

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder characterized by cholinergic dysfunction, amyloid-β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, mitochondrial impairment, metal dyshomeostasis, and chronic neuroinflammation, collectively leading to irreversible cognitive decline and neuronal degeneration. Despite decades of intensive research, currently approved therapeutic agents, including cholinesterase inhibitors (ChEI) and NMDA receptor antagonists, provide only symptomatic relief and do not substantially alter disease progression. Among the clinically available ChEI, rivastigmine (RIV) has attracted considerable attention owing to its dual inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), pseudo-irreversible mode of action, and established clinical efficacy in AD management. In recent years, RIV has emerged as a highly promising pharmacophoric scaffold for the development of multifunctional hybrid molecules designed according to the multi-target-directed ligand (MTDL) strategy to modulate multiple pathological pathways involved in AD simultaneously. This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment. The review places particular emphasis on the rational hybridization of RIV with diverse bioactive pharmacophores, including tryptamine, coumarin, flavonoids, melatonin, tacrine, ferulic acid, cannabidiol, benzimidazole, piperidine, aryloxacetic acid, and antioxidant motifs, to generate multifunctional agents with enhanced pharmacological profiles. The reviewed hybrids demonstrated remarkable multifunctional properties, including potent inhibition of AChE and BChE, suppression of Aβ aggregation, antioxidant and metal-chelating activities, anti-inflammatory effects, modulation of monoamine oxidases, neuroprotection, mitochondrial stabilization, and improved blood-brain barrier permeability. Several derivatives exhibited significantly greater potency and broader neuroprotective profiles than RIV itself, highlighting the therapeutic value of molecular hybridization approaches in AD drug discovery.

View source

Similar papers

Review Sep 2026

Cholinesterase Inhibitors in Alzheimer's Disease: Medicinal Chemistry, Mechanistic Insights, and Emerging Multitarget Strategies.

The need for rational drug design to develop multitargetdirected drugs that may have disease-modifying effects, to overcome the limitations of existing symptomatic cholinesterase-inhibitor monotherapy is underscored.

Anuradha Mehra, Rahul Sharma, Amit Mittal · 0 citations
Review Aug 2026

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...

Lalit Parihar, A. Singh, Sanjar Alam · 0 citations
Review Sep 2026

Beyond the Single-Target Approach: Polypharmacology and Multi-Target Therapeutics in Alzheimer's Disease.

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-beta aggregation, tau pathology, oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic degeneration. The limited clinical success of traditional single-target therapeutic approaches has highlighted th...

Renu Yadav, Jyoti Sinha, Km Deeksha · 0 citations
Review Aug 2026

Benzothiazole-Based Polyfunctional Agents in Alzheimer’s Therapy: Dual Diagnostic and Therapeutic Targeting of Aβ, Tau, and Neuroinflammation

The benzothiazole-derived polyfunctional compounds move in a direction that calls for speedy translation research towards the development of disease-modifying agents in AD, and challenges in off-target binding affinity, metabolic instability, Pglycoprotein efflux susceptibility, and the lack of in vivo studies in the l...

Meghana Devaraj, Prashant Tiwari, Sonal Dubey · 0 citations
Review Open access Oct 2026

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents.

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...

Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.